Abstract

A Taiwan team has shown that an antibody against IL-20 treated osteoporosis in mice by reducing signaling that plays a key role in bone resorption. Novo Nordisk has an anti-IL-20 mAb in Phase II for RA and now is considering whether to explore the bone loss indication.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call